Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
RESEARCH TOOLSreports
Lexeo Therapeutics, Inc. (LXEO) Stock Price & Analysis
83 Followers
LXEO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.00 - $22.33
Previous Close$11.19
Volume265.75K
Average Volume (3M)254.74K
Market Cap
$368.66M
Enterprise Value$335.78M
Total Cash (Recent Filing)$45.54M
Total Debt (Recent Filing)$12.66M
Price to Earnings (P/E)―
Beta2.83
Next Earnings
May 09, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding32,945,341
10 Day Avg. Volume218,942
30 Day Avg. Volume254,744
Standard Deviation0.22
R-Squared0.19
Alpha-0.00211
Financial Highlights & Ratios
Price to Book (P/B)-1.62
Price to Sales (P/S)816.08
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit513.42
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$23.33Price Target Upside108.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Lexeo Therapeutics, Inc. News
PremiumCompany Announcements
Lexeo Therapeutics Welcomes New Board Member Tim Van Hauwermeiren
Bulls Say, Bears Say
Bulls Say
Clinical DataLexeo Therapeutics reported interim data demonstrating signals of improvement in measures of cardiac hypertrophy and the validated cardiac biomarker troponin I.
Financial PerformanceAnalyst's recommendation raises the price target from $19 to $22.
Strategic PositionLexeo is targeting diseases such as Friedreich's ataxia cardiomyopathy and Alzheimer's disease, both of which have high unmet needs and would benefit greatly from an effective one-time treatment.
Bears Say
Alzheimer's Drug DevelopmentWhile cautiously expecting positive data, development in the Alzheimer's space has been challenging for decades, with only a few marginally beneficial therapies approved.
Clinical TrialsThe negative stock reaction is likely due to the implications of adding a higher third dose level to the trial, which delays advancement with expanded treatment of more patients at an optimal dose level.
ValuationThe valuation haircut is most driven by the removal of the fastest possible path to approval without Cohort 3.
---
Ownership Overview
20.58% Insiders
9.21% Mutual Funds
49.93% Other Institutional Investors
20.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $9.00 and its highest was $22.33 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is May 09, 2024 which is 74 days ago.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on Mar 11, 2024. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.697 by -$0.163.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -$0.74.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 32,945,340 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.697. Following the earnings report the stock price went up 5.685%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Among the largest hedge funds holding Lexeo Therapeutics, Inc.’s share is D1 Capital Partners LP. It holds Lexeo Therapeutics, Inc.’s shares valued at 39M.
---
Lexeo Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.33 (108.49% Upside)
$23.33 (108.49% Upside)
Blogger Sentiment
Bullish
LXEO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 871.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-58.63%
Trailing 12-Months
Asset Growth
173.96%
Trailing 12-Months
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
---
LXEO Stock 12 Month Forecast
Average Price Target
$23.33
▲(108.49% Upside)
Technical Analysis
BioLife Solutions
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering LXEO
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-10.42%
reiterated a buy rating 7 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -10.42% per trade.
---